Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19
María A. Pedrosa, Rita Valenzuela, Pablo Garrido‐Gil, et al.
Clinical Science (2021) Vol. 135, Iss. 3, pp. 465-481
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 49
Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19
Ana I. Rodríguez‐Pérez, Carmen M. Labandeira, María A. Pedrosa, et al.
Journal of Autoimmunity (2021) Vol. 122, pp. 102683-102683
Open Access | Times Cited: 77
Role of the Renin–Angiotensin–Aldosterone and Kinin–Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID
Samantha Cooper, Eleanor Boyle, S Jefferson, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8255-8255
Open Access | Times Cited: 58
Small‐Molecule Quenchers for Förster Resonance Energy Transfer: Structure, Mechanism, and Applications
Bin Fang, Yu Shen, Bo Peng, et al.
Angewandte Chemie International Edition (2022) Vol. 61, Iss. 41
Closed Access | Times Cited: 47
Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning
Maitray A. Patel, Michael J. Knauer, Michael Nicholson, et al.
Molecular Medicine (2023) Vol. 29, Iss. 1
Open Access | Times Cited: 25
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease
Carmen M. Labandeira, María A. Pedrosa, Aloia Quijano, et al.
npj Parkinson s Disease (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 30
The role of the brain renin-angiotensin system in Parkinson´s disease
José L. Labandeira‐García, Carmen M. Labandeira, María J. Guerra, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions
Mai Mohamed Abdelmoaty, Pravin Yeapuri, Jatin Machhi, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 37
Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course
Jelle Miedema, Marco W.J. Schreurs, Simone van der Sar–van der Brugge, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 34
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities
Rahul Kumar, Öznur Aktay-Cetin, Vaughn D. Craddock, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 1, pp. e1011063-e1011063
Open Access | Times Cited: 15
An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria
Rita Valenzuela, Ana I. Rodríguez‐Pérez, Maria A. Costa-Besada, et al.
Redox Biology (2021) Vol. 46, pp. 102078-102078
Open Access | Times Cited: 28
Bioinformatics Approach to Identify the Relationship among COVID-19, Acute Myocardial Infarction, and Acute Ischemic Stroke
Wen Chen, X. F. Ye
Next research. (2025), pp. 100178-100178
Closed Access
Transcriptomic studies revealed pathophysiological impact of COVID-19 to predominant health conditions
Zulkar Nain, Shital K. Barman, Md. Moinuddin Sheam, et al.
Briefings in Bioinformatics (2021) Vol. 22, Iss. 6
Open Access | Times Cited: 24
Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment
José L. Labandeira‐García, Carmen M. Labandeira, Rita Valenzuela, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 502-502
Open Access | Times Cited: 17
Neurological complications of COVID-19
Xingliang Dai, Xinxin Cao, Qian Jiang, et al.
QJM (2022) Vol. 116, Iss. 3, pp. 161-180
Open Access | Times Cited: 17
SARS-CoV-2 induces cardiomyocyte apoptosis and inflammation but can be ameliorated by ACE inhibitor Captopril
Xiaohan Huang, Wenxia Fan, Jing Ping Sun, et al.
Antiviral Research (2023) Vol. 215, pp. 105636-105636
Open Access | Times Cited: 9
Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies
Harry Ridgway, Graham J. Moore, Laura Kate Gadanec, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 5, pp. 437-459
Closed Access | Times Cited: 3
COVID‐19, obesity, and immune response 2 years after the pandemic: A timeline of scientific advances
Mayara Belchior‐Bezerra, Rafael Silva Lima, Nayara I. Medeiros, et al.
Obesity Reviews (2022) Vol. 23, Iss. 10
Open Access | Times Cited: 15
Plasma ACE2 species are differentially altered in COVID‐19 patients
María‐Salud García‐Ayllón, Óscar Moreno, Juan García‐Arriaza, et al.
The FASEB Journal (2021) Vol. 35, Iss. 8
Open Access | Times Cited: 19
AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability
María A. Pedrosa, Carmen M. Labandeira, Rita Valenzuela, et al.
Brain Behavior and Immunity (2022) Vol. 108, pp. 255-268
Open Access | Times Cited: 13
ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review
Lihua Qu, Chao Chen, Tong Yin, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11483-11483
Open Access | Times Cited: 17
Oral Lisinopril Raises Tissue Levels of ACE2, the SARS-CoV-2 Receptor, in Healthy Male and Female Mice
Steven Brooks, Rachel L. Smith, Aline dos Santos Moreira, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson’s disease models
Ana I. Rodríguez‐Pérez, Pablo Garrido‐Gil, María García-Garrote, et al.
Stem Cell Research & Therapy (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Do angiotensin-converting enzyme inhibitors not reduce the risk of pneumonia?
Shunichiro Tsukamoto
Hypertension Research (2024) Vol. 47, Iss. 10, pp. 2961-2963
Closed Access | Times Cited: 2
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
Fedor Šimko, Tomáš Baka
Clinical Science (2021) Vol. 135, Iss. 8, pp. 1009-1014
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top